Everything below concerns fatty acid oxidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
== Bare lymphocyte syndrome == One type of MHC class II deficiency, also called bare lymphocyte syndrome, is due to mutations in the genes that code for transcription factors that regulate the expression of the MHC class II genes. It results in the depletion of CD4 T cells and some immunoglobulin isotypes even though there are normal levels of both CD8 T cells and B cells present. Deficient MHC class II molecules are unable to present antigens to T cells and properly activate T cells. T cells are then unable to proliferate and secrete cytokines which normally participate in the immune response. Not only do the deficient MHC class II molecules affect the activation and proliferation of T cells but also the rest of the immune response cascade which includes B cells. Therefore, with this decrease in the number of T cells, the T cells cannot interact and activate the B cells. Normally when B cells are activated they divide, proliferate and differentiate, which includes the differentiation of these cells into plasma cells which are responsible for producing antibodies. However, when there is a deficiency in MHC class II molecules B cells are not activated and cannot differentiate into plasma cells which causes them to be deficient in antibodies which are unable to perform as they are expected. The only current form of treatment is a bone-marrow transplant; however, even this does not cure the disease and most patients do not live past age ten.
Since the discovery of Neanderthal remains in the 19th century, many scientists have supported the hypothesis of interbreeding between archaic and modern humans, also known as hybridization, admixture, or hybrid-origin theory. The linear view of human evolution came under scrutiny in the 1970s as different species of humans were discovered that made the simplistic concept increasingly unlikely. With the advent of advanced molecular biotechnology, whole-genome sequencing of Neanderthal and human genomes were performed that confirmed recent admixture between various human species. In 2010, evidence was published revealing unambiguous examples of interbreeding between archaic and modern humans during the Middle Paleolithic and early Upper Paleolithic. Research demonstrates that interbreeding occurred in several independent events that included Neanderthals, Denisovans, as well as several unidentified hominins. Modern day Eurasian genomes contain approximately 2% Neanderthal DNA, with traces of Denisovan heritage, while modern Melanesian people have an average of 4–6% Denisovan DNA. Denny represents the first ancient individual discovered whose parents belonged to two discrete species of humans, which will provide a unique opportunity for future comparative genetic studies. The discovery of Denny and other paleogenetic data acquired since 2010 show that human evolution should not be conceptualized as a simple linear or branched progression, but rather, as a complex interaction between related species over various periods of geographical isolation and convergence.
On 26 January 2016, having still not started a league match, Tottenham agreed a transfer fee with Newcastle United for Townsend, reportedly £12 million. Before the fee had been announced, Townsend had already tweeted a goodbye message, and stated "As soon as I knew of Newcastle's interest they were the only club I wanted to join...Two of the best positions you can play in football are centre-forward and left wing at Newcastle. I've got the chance. I could never turn that down. I can't wait to play my first game at St James' Park". The transfer was confirmed the following day, a five-and-a-half-year contract but with the club declining to disclose the fee. On signing, his new manager, Newcastle head coach Steve McClaren, said of Townsend that he is a "winger with an old-fashioned style. He can play on the right or the left, is two-footed, quick, very direct and loves taking on defenders and crossing the ball." According to Sky Sports, the transfer had been under negotiation for a week and Newcastle had initially wanted Townsend on loan, and then had a transfer offer of £10.5m rejected. Despite his debut for Newcastle being in a disappointing team performance in an away defeat, at the next match, his home debut, he was given a standing ovation after a Man of the Match performance which saw Newcastle climb out of the relegation places. His first goal for the club came in his third match, a shot from just outside the area, but it was just a 90th minute consolation goal in a 5–1 away defeat to Chelsea and the club was relegated to the Championship at the end of the season.
It performs antimicrobial functions in microorganisms like algae, fungi, bacteria, and gram-positive bacteria of different yeast species. Chitosan composite for tissue engineering: Chitosan powder blended with alginate is used to form functional wound dressings. These dressings create a moist, biocompatible environment which aids in the healing process. This wound dressing is also biodegradable and has porous structures that allows cells to grow into the dressing. Furthermore, thiolated chitosans (see thiomers) are used for tissue engineering and wound healing, as these biopolymers are able to crosslink via disulfide bonds forming stable three-dimensional networks.
Sources: en.wikipedia.org
243Am(15N,xn)258−xNo (x=4) This reaction was studied in 1966 at the FLNR. The team were able to detect 250Fm using chemical techniques and determined an associated half-life significantly higher than the reported 3 s by Berkeley for the supposed parent 254No. Further work later the same year measured 8.1 MeV alpha particles with a half-life of 30–40 s.
Eupolyphaga sinensis (Chinese: 土鳖虫), is a species of cockroach in the genus Eupolyphaga. They are most abundant in Central and Northern China, but also extend into South Russia, and likely Mongolia. It is the most widely distributed species within the genus. E. sinensis are mainly scavengers which feed on plant debris. It is well known for its use in traditional Chinese medicine. For commercial use they are bred and raised artificially, once mature they are collected, boiled in water, and dried either in the sun or by baking. Its common name in China, Tubiechong, is often used in reference to traditional Chinese medicine, it can also be used to generally mean a medicine which contains E. sinensis, along with other components. Tubiechong may also refer to several other cockroach species as medicine.
BV(relative) = relative BV of the test protein BV(reference) = percentage BV of reference protein (typically egg: 93.7%). BV(percentage) = percentage BV of the test protein While this conversion is simple it is not strictly valid due to the differences between the experimental methods. It is, however, suitable for use as a guideline.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.